(MENAFN- EIN Presswire) Douglas Insights
Some of the prominent companies operating in the market are Akari Therapeutics, Plc; Apellis Pharmaceuticals, Inc.; Amgen, Inc.; Alexion Pharmaceuticals, Inc.
ISLE OF MAN, October 17, 2022 / / -- What is Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment?
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, potentially fatal blood disease. The disease is characterized by the destruction of red blood cells, the formation of blood clots, and the dysfunction of bone marrow. PNH is associated with aplastic anaemia.
PNH is a highly uncommon, chronic blood disorder that affects roughly 20,000 people worldwide. Thrombosis, pancytopenia, and persistent intravascular hemolysis are the three most prominent manifestations of this life-threatening acquired disease. Around 10,000 cases of PNH are reported annually in North America and Europe, with an incidence of greater than 1,3 per million.
Size Analysis:
The global paroxysmal nocturnal hemoglobinuria (PNH) treatment market is expected to reach USD XX Million by 2028. The market is anticipated to witness a significant growth owing to the rising prevalence of the disease and the availability of effective treatments.
The treatment approach for PNH is evolving rapidly. It is driven by the development of biologics that target the underlying hemolytic defect or abnormal hematopoietic stem cell. However, the high cost of therapy and surgical procedures such as stem cell transplants (SCT), the unfavourable reimbursement environment in developing regions, and the adverse side effects of available treatments may hinder market growth over the forecast period. Furthermore, many patients do not recommend stem cell transplants because they are associated with high morbidity and mortality rates.
The only curative treatment for PNH patients is Allogeneic stem cell transplantation. The clinical outcomes of numerous SCT programmes indicate that this procedure is limited to a small number of patients with rare disorders. Only severe cases of PNH with life-threatening complications, such as progression to leukaemia or aplastic anaemia, are recommended to receive stem cell transplants. The indications for SCT have changed since the introduction of Soliris.
Compare and choose your best-fitting market report here-
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Drivers:
The primary drivers for the growth of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market are the increasing prevalence of blood disorders and the rising number of PNH cases.
Increasing incidence of blood and bone marrow disorders, an ageing population, and technological advances in stem cell transplantation are factors driving the PNH treatment market. However, the rising cost of medical equipment, particularly the surgical equipment required for stem cell transformation, the absence of reimbursement policies in developing regions, and the occurrence of side effects in related currently available treatments may impede the market for PNH treatments.
Regional Outlook:
The global Paroxysmal Nocturnal Hemoglobinuria (PNH) treatment market is segmented into four major regions: North America, Europe, Asia-Pacific, and Latin America.
North America is anticipated to be the largest market for PNH treatment owing to the availability of effective treatments and better healthcare infrastructure in the region. Moreover, the high awareness about PNH and its treatments among patients and physicians is expected to drive the market growth in this region.
Europe is also one of the major markets for PNH treatment due to the presence of a large number of PNH patients. In addition, initiatives by key market players to raise awareness about PNH and its treatments are expected to boost the market growth in Europe.
Asia-Pacific is expected to be a rapidly growing market for PNH treatment due to increasing healthcare expenditure, rising awareness about PNH, and expanding healthcare infrastructure in the region.
Latin America is also expected to witness significant growth in the PNH treatment market due to increasing prevalence of PNH and availability of effective treatments in the region.
Browse the full report here-
Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment Market Keyplayers Analysis:
Some of the prominent companies operating in the market are Akari Therapeutics, Plc; Apellis Pharmaceuticals, Inc.; Amgen, Inc.; Alexion Pharmaceuticals, Inc.; CinnaGen Co.; Ra Pharmaceuticals, Inc.; and Alnylam Pharmaceuticals, Inc..
Key Questions Answered In This Report
Covid 19 impact analysis on global Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment industry.
What are the current market trends and dynamics in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market and valuable opportunities for emerging players?
What is driving Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market?
What are the key challenges to market growth?
Which segment accounts for the fastest CAGR during the forecast period?
Which product type segment holds a larger market share and why?
Are low and middle-income economies investing in the Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment market?
Key growth pockets on the basis of regions, types, applications, and end-users
What is the market trend and dynamics in emerging markets such as Asia pacific, Latin America, and Middle East & Africa?
Unique data points of this report
Statistics on Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment and spending worldwide
Recent trends across different regions in terms of adoption of Paroxysmal Nocturnal Hemoglobinuria (PNH) Treatment across industries
Notable developments going on in the industry
Attractive investment proposition for segments as well as geography
Comparative scenario for all the segments for years 2018 (actual) and 2031 (forecast)
Table of content:
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Treatment
3.7.2 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK
5.1. Impact Analysis of Covid-19 Outbreak
5.1.1. Direct Impact on Production
5.1.2. Supply Chain and Market Disruption
5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis
6 . GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY TREATMENT
6.1 Overview by Treatment
6.2 Historical and Forecast Data
6.3 Analysis by Treatment
6.4 Medication Historic and Forecast Sales by Regions
6.5 Stem Cell Transplant Historic and Forecast Sales by Regions
6.6 Blood Transfusion Historic and Forecast Sales by Regions
7 . GLOBAL PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT MARKET ANALYSIS BY GEOGRAPHY
7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
7.3.1. Overview, Historic and Forecast Sales Analysis
7.3.2. North America By Segment Sales Analysis
7.3.3. North America By Country Sales Analysis
7.3.4. United State Sales Analysis
7.3.5. Canada Sales Analysis
7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
7.4.1. Overview, Historic and Forecast Sales Analysis
7.4.2. Europe by Segment Sales Analysis
7.4.3. Europe by Country Sales Analysis
7.4.4. United Kingdom Sales Analysis
7.4.5. France Sales Analysis
7.4.6. Germany Sales Analysis
7.4.7. Italy Sales Analysis
7.4.8. Russia Sales Analysis
7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
7.5.1. Overview, Historic and Forecast Sales Analysis
7.5.2. Asia Pacific by Segment Sales Analysis
7.5.3. Asia Pacific by Country Sales Analysis
7.5.4. China Sales Analysis
7.5.5. India Sales Analysis
7.5.6. Japan Sales Analysis
7.5.7. South Korea Sales Analysis
7.5.8. Australia Sales Analysis
7.5.9. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
7.6.1. Overview, Historic and Forecast Sales Analysis
7.6.2. Latin America by Segment Sales Analysis
7.6.3. Latin America by Country Sales Analysis
7.6.4. Brazil Sales Analysis
7.6.5. Argentina Sales Analysis
7.6.6. Peru Sales Analysis
7.6.7. Chile Sales Analysis
7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
7.7.1. Overview, Historic and Forecast Sales Analysis
7.7.2. Middle East & Africa by Segment Sales Analysis
7.7.3. Middle East & Africa by Country Sales Analysis
7.7.4. Saudi Arabia Sales Analysis
7.7.5. UAE Sales Analysis
7.7.6. Israel Sales Analysis
7.7.7. South Africa Sales Analysis
7.7.8. Rest Of Middle East And Africa Sales Analysis
8 . COMPETITIVE LANDSCAPE OF THE PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT COMPANIES
8.1. Paroxysmal Nocturnal Hemoglobinuria (Pnh) Treatment Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments
9 . COMPANY PROFILES OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) TREATMENT INDUSTRY
9.1. Top 10 Company Share Analysis
9.2. Market Concentration Rate
9.3. Alexion Pharmaceuticals Inc.
9.3.1. Company Overview
9.3.2. Company Revenue
9.3.3. Products
9.3.4. Recent Developments
9.4. Akari Therapeutics
9.4.1. Company Overview
9.4.2. Company Revenue
9.4.3. Products
9.4.4. Recent Developments
9.5. Apellis.
9.5.1. Company Overview
9.5.2. Company Revenue
9.5.3. Products
9.5.4. Recent Developments
9.6. Achillion.
9.6.1. Company Overview
9.6.2. Company Revenue
9.6.3. Products
9.6.4. Recent Developments
9.7. Others
9.7.1. Company Overview
9.7.2. Company Revenue
9.7.3. Products
9.7.4. Recent Developments
…………..Continued
Access the complete market research report here-
Know the Pain & Gain of Consumer: -
About -
Douglas insights UK limited is the first company to provide comparison of market research reports by table of content, price, ratings and number of pages. We understand the value of time. Productivity and efficiency are possible when you take prompt and assured decisions. With our advanced algorithm, filters, and comparison engine, you can compare your preferred reports simultaneously, based on publisher rating, published date, price, and list of tables. Our data portal enables you to find and review the reports from several publishers. You can evaluate numerous reports on the same screen and select the sample for your best match.
Isabella Hawke
Douglas Insights
+44 7624 248772
Visit us on social media: